Novartis Rejiggers Pharma To Favor Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.
You may also be interested in...
Novartis Oncology Strategy: Focus On The Microenvironment
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.
European Notebook: Bayer Bids For Monsanto; Biosimilar Uptake Still Sluggish; EMA Enters Drug Pricing Debate
The restructuring of business portfolios occupies Europe's big pharma companies, while the region's health providers look to improve the uptake of biosimilars, and European regulators suggest ways to use greater market competition to tame high drug prices. Plus Brexit, trade agreements, pharmacovigilance and more in this month's column.
Pfizer's Increasingly Specialist Focus
Pfizer's brand-new oncology business unit appears to be the linchpin in its transformation from primary care behemoth to specialty powerhouse. The Big Pharma also followed this up with the announcement that it was cutting early-stage R&D programs focused on obesity, bone health, and what has been its mainstay--cardiovascular disease. Together, these moves should be viewed as the most extreme example of the industry's flight from primary care medicine into the safer haven of specialty-focused pharmaceuticals,